FDA Inspection 1191762 — Anna Sediva, M.D., Ph.D.
The FDA completed an inspection of Anna Sediva, M.D., Ph.D. on November 8, 2022 in Prague 5. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 8, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Prague 5 (Czech Republic)
Additional Details
Clinical Investigator (CI)